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ORRESPONDENCES
ong term effects of nocturnal
ypoxia and urinary uric acid
Third,  patients  were  contacted  after  5  years  by  the
authors  with  a  questionnaire,  including  information  on  the
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4xcretion: How much linked to
OPD  and OSAS?
ear  Editor,
ypoxia  is  an  important  topic  both  physiologically  and
linically  in  obstructive  sleep  apnea  syndrome  (OSAS)  and
hronic  obstructive  pulmonary  disease  (COPD).  Uric  acid
UA)  is  the  end  product  of  adenosine  triphosphate  (ATP)
egradation,  which  it  has  been  suggested,  correlates  with
cute  and  long  term  effects  of  hypoxia.1,2 The  potential
pplication  of  this  metabolite  in  patients  who  suffer  noc-
urnal  hypoxemia  could  be  a  useful  marker  for  nocturnal
ypoxemia  follow-up.
We  read  with  great  interest  the  article  by  Ozanturk
t  al.3 and  congratulate  the  authors  on  their  study.  The
uthors  investigated  the  association  of  UA  metabolites  with
octurnal  hypoxemia,  apnea--hypopnea  index,  noninvasive
echanical  ventilation  (NIMV)  usage,  and  ﬁve-year  mortal-
ty  in  COPD  and  OSAS  patients.  We  are  in  agreement  that  UA
xcretion  is  a  practical  marker  of  tissue  hypoxia  and  could  be
seful  in  the  management  of  OSAS  and  COPD  patients.  How-
ver,  we  think  that  there  are  some  additional  factors  during
his  long  term  observation  that  could  have  inﬂuenced  the
erformance  of  UA  metabolism  described  by  Ozanturk  et  al.3
First,  the  mechanism  of  nocturnal  hypoxemia  within
OPD  and  OSAS  patients  is  not  the  same.  Although  these
wo  diseases  develop  hypoxemia,  they  do  not  have  a  similar
attern  and  compensatory  mechanism.  For  example,  COPD
ypoxemia  is  progressive,  worsening  mainly  by  inﬂammatory
xacerbations,  while  OSAS  hypoxemia  is  nocturnal  and  inter-
ittent,  without  inﬂammatory  exacerbations.  We  consider
hat  this  is  a  controversial  aspect  worth  discussing,  which
ay  inﬂuence  UA  metabolism.
Second,  the  criterion  for  nocturnal  hypoxemia  was
eﬁned  by  the  authors  as  a  percentage  of  time  spent  below
xyhemoglobin  saturation  of  90%  for  >10%  of  sleep  time.
lthough,  there  is  no  universal  deﬁnition  in  the  grading  of
octurnal  intermittent  hypoxemia,2 we  feel  the  level  used
y  the  authors  needs  more  precise  deﬁnition.  Additionally,
SAS  and  COPD  laboratory  protocols  vary  greatly  in  the  dura-
ion  of  hypoxia  exposure,  number  of  hypoxia  episodes  per
ay,  and  the  total  number  of  days  of  exposure.2
173-5115/© 2016 Sociedade Portuguesa de Pneumologia. Published by 
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)IMV  treatment  used.  But  we  have  no  information  of  long-
erm  adherence  to  PAP.  In  relation  to  COPD  patients,  this
rticle  does  not  mention  the  need  for  long-term  oxygen
herapy,  and  if  the  patients  were  on  maximal  pharmacolog-
cal  and  non-pharmacological  therapy  according  to  disease
everity.  Additionally,  in  the  literature  there  was  evidence
hat  UA  levels  were  higher  in  COPD  patients  with  more
evere  airﬂow  limitation  and  frequent  exacerbations.  It
ould  be  interesting  to  include  a  subgroup  analysis  of  COPD
atients  using  the  current  GOLD  classiﬁcation  in  a  future
tudy.
Finally,  we  think  that  it  is  essential  to  consider  some
dditional  cofactors  that  may  have  inﬂuenced  these  results,
ncluding  cardiovascular  factors  control,  such  as  hyperten-
ion,  which  may  differ  among  groups  over  the  5  years  of
tudy.4 Also  the  impact  of  long-term  dietary  factors  on  UA
etabolism  needs  to  be  taken  into  account.5
The  complexity  of  UA  metabolism  and  its  association  with
octurnal  intermittent  hypoxemia  and  non-intermittent
ypoxemia  represent  an  original  approach,  but  further
rospective  clinical  trials  are  needed  to  conﬁrm  these
esults.
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Reply to the letter ‘‘Long term
effects of nocturnal hypoxia
and urinary uric acid excretion:
How much linked to COPD and
OSAS?’’
Dear  Editor,
We  have  read  the  letter  titled  ‘‘Long  term  effects  of  noc-
turnal  hypoxia  and  urinary  uric  acid  excretion:  How  much
linked  to  COPD  and  OSAS?’’  regarding  our  manuscript  ‘Uri-
nary  uric  acid  excretion  as  an  indicator  of  severe  hypoxia
and  mortality  in  patients  with  obstructive  sleep  apnea  and
chronic  obstructive  pulmonary  disease’.  First,  we  would  like
to  thank  to  Dr  Gomes  and  colleagues  for  their  interest  in
our  study.  We  are  grateful  for  the  insightful  comments  to
our  article  and  are  happy  to  respond  to  their  comments  as
follows.
1.  First  of  all  COPD  and  OSA  have  different  mechanisms
for  hypoxemia  as  mentioned.  Furthermore  intermittent
and  chronic  hypoxemia  has  different  effect  on  diseases
too.  It  would  be  very  useful  to  compare  these  results  on
uric  acid  levels  in  both  diseases,  but  unfortunately  as
we  mentioned  in  our  manuscript  we  did  not  have  enough
participants  to  make  this  sub-group  analysis.
2.  As  the  author  mentioned  there  is  no  universal  deﬁnition
in  the  grading  of  nocturnal  intermittent  hypoxemia.1 It  is
neither  wrong  nor  faultless  to  use  >10%  or  >30%  of  sleep
time.2--3 It  would  be  more  useful  to  use  both  criteria  and
make  further  studies  with  new  GOLD  combined  assess-
ment  strategy.
4. Hypertension  was  the  case  for  approximately  15%  of
our  patients,  which  could  decrease  UA  excretion.  How-
ever,  the  analysis  did  not  reveal  a  signiﬁcant  difference
between  hypertensive  and  normotensive  patients.
We  believe  that  further  clinical  trials  investigating  the
effect  of  nocturnal  progressive  and  intermittent  hypox-
emia  on  COPD  and  OSA  patients  are  needed  to  conﬁrm  our
results.
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